1. Paliperidone palmitate use in pregnancy in a woman with schizophrenia
- Author
-
Mustafa Kadri Gücer, Omer Gecici, Murat Kuloglu, Şima Ceren Pak, Fatih Canan, and Aslı Karadağ Özdemir
- Subjects
Adult ,Male ,medicine.medical_specialty ,Pediatrics ,medicine.drug_class ,medicine.medical_treatment ,Atypical antipsychotic ,Injections, Intramuscular ,Drug Administration Schedule ,Treatment compliance ,Pregnancy ,Paliperidone Palmitate ,medicine ,Humans ,Psychiatry ,Antipsychotic ,Psychiatric Status Rating Scales ,business.industry ,Obstetrics and Gynecology ,medicine.disease ,Pregnancy Complications ,Psychiatry and Mental health ,Treatment Outcome ,Schizophrenia ,Psychiatric status rating scales ,Gestation ,Female ,Schizophrenic Psychology ,business ,Antipsychotic Agents - Abstract
Long-acting antipsychotic use in schizophrenia has become an advantage for treatment compliance and convenient administration of the drugs. There is no data on paliperidone palmitate (PP) use in pregnancy, which is the longest-acting (i.e., 1 month) atypical antipsychotic. In this case report, we aim to present a patient diagnosed with schizophrenia who had been using PP before and during her pregnancy until week 28 of gestation and gave birth to a male baby that weighed 3000 g at 39 weeks. As far as we know, this is the first case report on PP use during pregnancy.
- Published
- 2014